Procrit (epoetin alfa) carries serious, well-documented risks. The FDA has placed its strongest safety warning, a boxed warning, on the drug for increased risk of death, heart attack, stroke, blood clots, and tumor progression or recurrence. These risks are real enough that several clinical trials testing the drug were stopped early because patients receiving it were dying at higher rates than those on placebo. That said, Procrit remains an approved and useful medication for specific types of anemia, and the danger depends heavily on how it’s used, at what dose, and in what medical context.
Why Procrit Exists and What It Does
Procrit is a lab-made version of erythropoietin, a hormone your kidneys naturally produce to stimulate red blood cell production. It’s prescribed to treat anemia in people with chronic kidney disease, in cancer patients receiving chemotherapy, and sometimes before certain surgeries to reduce the need for blood transfusions. The drug works, often effectively, at raising red blood cell counts. The problem is what can happen along the way.
Blood Clots, Heart Attack, and Stroke
The most common serious risk with Procrit is blood clots. More red blood cells make blood thicker and stickier, which increases the chance of clots forming in veins, arteries, and dialysis access sites. This translates into higher rates of deep vein thrombosis, heart attacks, and strokes across nearly every patient group studied.
In kidney disease patients on hemodialysis who were given Procrit to reach a higher red blood cell target (a hematocrit of 42% versus 30%), access site clotting jumped from 29% to 39%, and other clotting events rose from 18% to 22%. Non-fatal heart attacks were also more frequent in the higher-target group (3.1% versus 2.3%).
For kidney disease patients not on dialysis, a trial of over 1,400 people found that targeting a hemoglobin of 13.5 g/dL instead of 11.3 g/dL led to a 30% higher rate of major cardiovascular events, including death, heart attack, stroke, and hospitalization for heart failure. Eighteen percent of patients in the higher-target group experienced one of these events, compared to 14% in the lower-target group.
Stroke risk deserves special attention. In the TREAT trial, which studied a similar drug (darbepoetin) in kidney disease patients with type 2 diabetes, patients receiving the medication experienced double the rate of stroke compared to placebo. That finding, published in Circulation, was highly statistically significant and has shaped how cautiously these drugs are now prescribed.
Increased Mortality in Cancer Patients
The dangers of Procrit are particularly stark in cancer. Multiple clinical trials have shown that cancer patients receiving the drug can have shorter survival times and faster tumor progression, not just more blood clots.
In a study of women with metastatic breast cancer (the BEST study), the trial was stopped early because patients on Procrit were dying at more than twice the rate of those on placebo in the first four months: 8.7% versus 3.4%. Fatal blood clots were also far more common (1.1% versus 0.2%). At 12 months, survival was 70% in the Procrit group compared to 76% on placebo.
A study in cervical cancer patients was also terminated early after thromboembolic events hit 19% in the Procrit group versus 9% in the control group. In head and neck cancer, one trial found that tumor progression was 69% more likely in patients receiving the drug.
A large meta-analysis pooling 57 randomized trials and over 9,300 cancer patients found a 67% increase in the relative risk of blood clots among those treated with erythropoiesis-stimulating agents like Procrit. When researchers looked specifically at the seven trials designed to measure survival, the pooled data showed a 16% higher risk of death. Six additional studies were stopped early because of safety concerns, and those showed a 34% higher risk of death in treated patients.
The cancers where problems have been documented include breast, lung, head and neck, lymphoid, and cervical cancers. The FDA now requires that cancer patients be counseled about these risks and sign an acknowledgment form before starting treatment.
The Hemoglobin Target Matters
Much of Procrit’s danger comes from pushing red blood cell levels too high. Clinical trials consistently show that targeting hemoglobin levels of 13 g/dL or above dramatically increases the risk of cardiovascular events and death. Current guidelines call for using the lowest dose necessary to avoid blood transfusions rather than trying to normalize hemoglobin levels completely.
This is a shift from how the drug was used in its early years, when doctors often aimed for near-normal blood counts. The evidence now clearly shows that more aggressive dosing doesn’t make patients feel proportionally better but does make them significantly more likely to have a serious complication.
Blood Pressure Spikes
Procrit commonly raises blood pressure, especially in people with chronic kidney disease. This can happen even if you’ve never had hypertension before, and it can make existing blood pressure harder to control with medication. For people who already have uncontrolled high blood pressure, Procrit is contraindicated entirely, meaning it should not be used at all.
Rare but Severe Reactions
In uncommon cases, the body can develop antibodies against Procrit that also neutralize the natural erythropoietin your body makes. This leads to a condition called pure red cell aplasia, where the bone marrow essentially stops producing red blood cells altogether. The resulting anemia can be worse than what the drug was prescribed to treat in the first place, and it doesn’t resolve by simply stopping the medication. Anyone who has developed this condition from Procrit or a similar drug should never take it again.
Serious allergic reactions are also possible, though rare. These are another absolute contraindication for future use.
Who Should Not Take Procrit
Beyond uncontrolled hypertension and prior allergic reactions, Procrit should not be used in people scheduled for heart or blood vessel surgery, as the clotting risk in that context is too high. Multidose vials of the drug should not be given to pregnant or breastfeeding women or to infants. People undergoing spinal surgery showed higher rates of deep vein thrombosis on Procrit (4.7% versus 2.1%), so clot prevention measures are considered essential in surgical settings.
If you have heart disease, a history of seizures or stroke, or high blood pressure of any degree, these conditions don’t necessarily prevent use but do increase your risk profile and require closer monitoring.
Putting the Risk in Context
Procrit is not a casual medication. It carries real, quantifiable dangers that have led to multiple trials being halted, an FDA boxed warning, and significant restrictions on how it can be prescribed. At the same time, severe anemia itself is dangerous, and for people who would otherwise need repeated blood transfusions, Procrit can still be the better option when used conservatively at the lowest effective dose, with careful blood pressure and hemoglobin monitoring throughout treatment.
The core issue is not that Procrit should never be used. It’s that the drug becomes substantially more dangerous when it’s used aggressively, when hemoglobin targets are set too high, or when it’s given to cancer patients whose tumors may respond to the growth signals it triggers. The margin between helpful and harmful is narrower with this drug than with most.